Norgestimate And Ethinyl Estradiol Kit
Product Images NDC 42291-590

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Norgestimate And Ethinyl Estradiol (NDC 42291-590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Inner (590 28 Inner Carton)

Packaging label for norgestimate and ethinyl estradiol tablets USP, available in a kit containing a 28-tablet blister card. Tablets contain varying strengths of norgestimate (0.18 mg, 0.215 mg, or 0.25 mg) combined with 0.035 mg ethinyl estradiol. The label identifies AvKARE as the manufacturer and includes storage instructions, barcode, and NDC 42291-590.*

FDA Label Image

Large (591 84 Large Carton)

Packaging label for norgestimate and ethinyl estradiol tablets, USP in kit form by AvKARE. The label lists strengths of 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.25 mg/0.035 mg. The kit contains three blister cards with 28 tablets each. The carton includes usage storage instructions and manufacturing details from AvKARE, a product of Spain.*

FDA Label Image

Blister (Blister Pack)

Illustration showing a 4-week dosing schedule for norgestimate and ethinyl estradiol tablets USP with detailed dosages per tablet. It includes circular markers for each day of the week arranged over 4 rows labeled Week 1 to Week 4. Weeks 1 to 3 have white circles for daily dosing, while Week 4 has gray circles indicating inactive or placebo pills. The diagram guides a weekly daily sequence from Sunday through Saturday to organize tablet intake.*

FDA Label Image

Chart 1

A vertical arrow chart illustrating pregnancy frequency per 100 women in one year, from fewer than 1 to 85 or more pregnancies. The chart categorizes birth control methods by effectiveness: from most effective methods such as implants, injections, intrauterine devices, and sterilization; to moderately effective methods including birth control pills, skin patch, vaginal ring with hormones; to less effective methods such as condoms and diaphragm; and finally to no birth control methods like abstinence during fertile days, spermicide, withdrawal, or no birth control, resulting in more pregnancies.*

FDA Label Image

Ethinyl (Ethinyl Estradiol)

Chemical structure of ethinyl estradiol, depicted as a molecular diagram with labeled atoms and bonds representing its steroid framework and functional groups.*

FDA Label Image

Figure 2

A forest plot figure illustrating the relative risk (RR), odds ratio (OR), and hazard ratio (HR) of breast cancer associated with combined oral contraceptive use from multiple cohort studies, comparing females with current or past use versus those who never used. The horizontal axis shows effect estimates ranging from -1.5 to 2, with each study's risk estimate and confidence interval displayed as points and horizontal lines.*

FDA Label Image

Norgestimate (Norgestimate)

Chemical structure of norgestimate, the active ingredient in the product norgestimate and ethinyl estradiol. The diagram shows the molecular framework including labeled atoms and bonds characteristic of norgestimate's steroid structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.